Sugiyama Shinichi, Beppu Toru, Ishiko Takatoshi, Takahashi Masashi, Masuda Toshiro, Hirata Takahumi, Imai Katsunori, Hayashi Hiromitsu, Takamori Hiroshi, Kanemitsu Keiichiro, Hirota Masahiko, Murakami Ryuji, Baba Yuji, Oya Natsuo, Yamashita Yasuyuki, Baba Hideo
Department of Gastroenterological Surgery, Faculty of Medical and Pharmaceutical Sciences, Kumamoto University, Japan.
Hepatogastroenterology. 2007 Sep;54(78):1779-82.
BACKGROUND/AIMS: The purpose of this study is to evaluate the effect of radiation therapy (RT) for tumor thrombosis (TT) in the major portal vein (PV) or inferior vena cava (IVC) from unresectable hepatocellular carcinoma. METHODOLOGY: Fifteen HCC patients with main PVTT (n = 10) and IVCTT (n 5) were treated with three-dimensional conformal RT between 2001 and 2004. The mean dose was 38.5 Gy (range 28 to 54Gy). The concurrent therapies to intrahepatic tumor included transcatheter arterial chemoembolization (TACE) in 7, TACE + hepatic arterial infusion in 2 and systemic chemotherapy in 1 patient. The therapeutic effect was assessed by tumor regression for TT. RESULTS: An objective response was observed in 3 of 15 patients (20%). There were no patients with progressive disease. The median survival time was 10 months. In 12 cases with stable disease, time to progression (TTP) estimated above 6 months were 42% (5/12 cases). In univariate analysis, therapeutic effect and TTP were affected to survival time. All patients did not have severe deterioration of liver function. CONCLUSIONS: In the current study, we concluded that RT was superior treatment in terms of local control capability and was useful to continue further treatment because RT did not make liver function worse.
背景/目的:本研究旨在评估放射治疗(RT)对不可切除肝细胞癌主要门静脉(PV)或下腔静脉(IVC)肿瘤血栓形成(TT)的疗效。 方法:2001年至2004年间,15例主要门静脉肿瘤血栓形成(n = 10)和下腔静脉肿瘤血栓形成(n = 5)的肝癌患者接受了三维适形放疗。平均剂量为38.5 Gy(范围28至54 Gy)。肝内肿瘤的同步治疗包括7例经动脉化疗栓塞(TACE)、2例TACE + 肝动脉灌注和1例全身化疗。通过肿瘤血栓形成的肿瘤消退评估治疗效果。 结果:15例患者中有3例(20%)观察到客观缓解。没有疾病进展的患者。中位生存时间为10个月。在12例疾病稳定的患者中,估计进展时间(TTP)超过6个月的为42%(5/12例)。单因素分析中,治疗效果和TTP影响生存时间。所有患者肝功能均未出现严重恶化。 结论:在本研究中,我们得出结论,放射治疗在局部控制能力方面是较好的治疗方法,并且由于放射治疗不会使肝功能恶化,有助于继续进一步治疗。
Hepatogastroenterology. 2007-9
Int J Radiat Oncol Biol Phys. 2009-11-18
Int J Radiat Oncol Biol Phys. 2012-2-28
World J Gastroenterol. 2015-3-28
World J Surg Oncol. 2013-10-5